# A Phase II Study With Low-dose Recombinant Human IL-2 for the Treatment of Primary Sjögren's Syndrome

> **NCT02464319** · PHASE2 · COMPLETED · sponsor: **Peking University People's Hospital** · enrollment: 60 (actual)

## Conditions studied

- Primary Sjögren's Syndrome

## Interventions

- **DRUG:** hrIL-2 active
- **DRUG:** hrIL-2 placebo

## Key facts

- **NCT ID:** NCT02464319
- **Lead sponsor:** Peking University People's Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-06-01
- **Primary completion:** 2017-03-31
- **Final completion:** 2017-08-31
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2018-03-15

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02464319

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02464319, "A Phase II Study With Low-dose Recombinant Human IL-2 for the Treatment of Primary Sjögren's Syndrome". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02464319. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*